(Reuters) – Thermo Fisher Scientific (N:) said on Thursday it has terminated its acquisition agreement for German genetic testing company Qiagen (DE:) as the minimum acceptance threshold to its tender offer were not met.
Thermo Fisher’s revised offer had valued Qiagen at 11.3 billion euros ($ 13.38 billion).
Qiagen’s shares fell 1.5% in premarket trading after the announcement.
($ 1 = 0.8445 euros)
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.